What is China NT Pharma Group Co Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, China NT Pharma Group Co's Enterprise Value is HK$781.03 Mil.
China NT Pharma Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-23.36 Mil. Therefore, China NT Pharma Group Co's EV-to-EBIT ratio for today is -33.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of China NT Pharma Group Co's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's Enterprise Value falls into.
China NT Pharma Group Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
China NT Pharma Group Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
China NT Pharma Group Co's EV-to-EBIT for today is
China NT Pharma Group Co's current Enterprise Value is HK$781.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-23.36 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
China NT Pharma Group Co's EV-to-EBITDA for today is:
China NT Pharma Group Co's current Enterprise Value is HK$781.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-23.36 Mil.
China NT Pharma Group Co's current Enterprise Value is HK$781.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$40.81 Mil.
China NT Pharma Group Co's current Enterprise Value is HK$781.03 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$36.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of China NT Pharma Group Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01011 has been successfully added to your 